genzyme corp tolevamer disappoints in first late stage trial reuters genzyme corp said its experimental drug tolevamer designed to treat diarrhea associated with the intestinal bacteria clostridium difficile worked no better than a standard antibiotic the cambridge mass firms shares fell &# or to &# in p m composite trading friday on the nasdaq stock exchange results from the first of two late stage trials showed the drug was no more effective than the standard antibiotic vancomycin "these are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future " said henri a termeer chairman and chief executive 
